|
JP2008231067A
|
|
Manufacturing method of lyophilized formulation containing quionolone
|
|
TW200813005A
|
|
Hydrate for pharmaceutical compositions
|
|
JP2007282628A
|
|
Method for screening anti-cancer agent
|
|
JP2007136245A
|
|
Intravenous drip set
|
|
JP2008212033A
|
|
Fluorescent-labeled polynucleotide
|
|
JP2007254461A
|
|
Levofloxacin-containing tablet
|
|
TW200806611A
|
|
Novel amidopropionic acid derivatives and medicine containing the same
|
|
JP2007231001A
|
|
Bone absorption inhibitor
|
|
JP2008184388A
|
|
Method for producing tetra-substituted pyrrolidines
|
|
JP2008102114A
|
|
Method for diagnosing mucopolysaccharidosis
|
|
JP2007070369A
|
|
Diamine derivatives
|
|
JP2008150296A
|
|
Method for producing tetrasubstituted pyrrolidine compound
|
|
WO2007069635A1
|
|
Vla-4 inhibitory drug
|
|
JP2008133211A
|
|
Method for producing tetra-substituted pyrrolidine derivative
|
|
WO2007055362A1
|
|
Method and apparatus for detecting or determining polypeptide
|
|
JP2009184925A
|
|
5-(1h-1,2,3-triazol-4-yl)-1h-pyrazole derivative
|
|
WO2007052561A1
|
|
Method for prevention of myocardial hypertrophy by inhibiting interaction between slim1 and usp, and agent for prevention of myocardial hypertrophy
|
|
TW200730503A
|
|
Tricyclic compound
|
|
JP2008100967A
|
|
Halogenobenzenesulfonamide derivative
|
|
JP2008100950A
|
|
Prophylactic and/or treating agent for influenza virus infectious disease
|
